DK1476541T3 - Cytokin (zcytor17-ligand) - Google Patents

Cytokin (zcytor17-ligand)

Info

Publication number
DK1476541T3
DK1476541T3 DK03729693T DK03729693T DK1476541T3 DK 1476541 T3 DK1476541 T3 DK 1476541T3 DK 03729693 T DK03729693 T DK 03729693T DK 03729693 T DK03729693 T DK 03729693T DK 1476541 T3 DK1476541 T3 DK 1476541T3
Authority
DK
Denmark
Prior art keywords
seq
amino acid
acid residues
cytokine
zcytor17 ligand
Prior art date
Application number
DK03729693T
Other languages
Danish (da)
English (en)
Inventor
Francis J Grant
Joseph L Kuijper
Julia E Novak
Stacey R Dillon
Cindy A Sprecher
Maria M Dasovich
Angela K Hammond
Jane A Gross
Original Assignee
Zymogenetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymogenetics Inc filed Critical Zymogenetics Inc
Application granted granted Critical
Publication of DK1476541T3 publication Critical patent/DK1476541T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G01N33/567—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds utilising isolate of tissue or organ as binding agent
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
DK03729693T 2002-01-18 2003-01-21 Cytokin (zcytor17-ligand) DK1476541T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US35032502P 2002-01-18 2002-01-18
US37532302P 2002-04-25 2002-04-25
US43531502P 2002-12-19 2002-12-19
PCT/US2003/001984 WO2003060090A2 (en) 2002-01-18 2003-01-21 Novel cytokine zcytor17 ligand

Publications (1)

Publication Number Publication Date
DK1476541T3 true DK1476541T3 (da) 2008-11-03

Family

ID=27407940

Family Applications (3)

Application Number Title Priority Date Filing Date
DK08102636.1T DK1961811T3 (da) 2002-01-18 2003-01-21 Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
DK10168189.8T DK2230299T3 (da) 2002-01-18 2003-01-21 Hidtil ukendt cytokin ZCYTOR17-ligand
DK03729693T DK1476541T3 (da) 2002-01-18 2003-01-21 Cytokin (zcytor17-ligand)

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DK08102636.1T DK1961811T3 (da) 2002-01-18 2003-01-21 Cytokinligand til behandling af asthma og luftvejs-hyper-responsivitet
DK10168189.8T DK2230299T3 (da) 2002-01-18 2003-01-21 Hidtil ukendt cytokin ZCYTOR17-ligand

Country Status (21)

Country Link
US (12) US7064186B2 (no)
EP (3) EP2230299B1 (no)
JP (1) JP4795641B2 (no)
KR (1) KR101013401B1 (no)
CN (2) CN101843895A (no)
AT (3) ATE536406T1 (no)
AU (2) AU2003225525B2 (no)
BR (1) BR0306979A (no)
CA (1) CA2473686C (no)
CY (1) CY1112833T1 (no)
DE (2) DE60333963D1 (no)
DK (3) DK1961811T3 (no)
ES (3) ES2310660T3 (no)
IL (3) IL163066A (no)
NO (1) NO332266B1 (no)
PL (1) PL211833B1 (no)
PT (1) PT2230299E (no)
RU (2) RU2360923C2 (no)
SI (1) SI2230299T1 (no)
WO (1) WO2003060090A2 (no)
ZA (1) ZA200405695B (no)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1188830E (pt) 1999-06-02 2010-04-09 Chugai Pharmaceutical Co Ltd Nova proteína nr10 receptora da hemopoietina
WO2001023556A1 (fr) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Nouvelle proteine receptrice d'hemopoietine (nr12)
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
RU2360923C2 (ru) 2002-01-18 2009-07-10 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
US7494804B2 (en) * 2002-01-18 2009-02-24 Zymogenetics, Inc. Polynucleotide encoding cytokine receptor zcytor17 multimer
US9738700B2 (en) 2002-01-18 2017-08-22 Zymogenetics Inc. ZCYTOR17 heterodimeric cytokine receptor
WO2005040380A1 (ja) * 2003-10-29 2005-05-06 Bml, Inc. げっ歯類動物の免疫応答調節蛋白質
JP2007068402A (ja) * 2003-12-26 2007-03-22 Bml Inc 免疫応答調節蛋白質
US20060269991A1 (en) * 2004-11-03 2006-11-30 Boehringer Ingelheim Pharmaceuticals, Inc. T cell protein and nucleotides encoding the same
US20060228329A1 (en) * 2005-01-28 2006-10-12 Brady Lowell J Homogeneous preparations of IL-31
AU2012202218B2 (en) * 2005-02-14 2014-05-22 National Jewish Medical And Research Center Methods Of Treating Diseases Which Are Mediated By Cutaneous Lymphocyte Antigen Positive Cells
MX2007009718A (es) * 2005-02-14 2007-09-26 Zymogenetics Inc Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra.
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
WO2006113671A2 (en) * 2005-04-15 2006-10-26 Oncomethylome Sciences, S.A. Methylation markers for diagnosis and treatment of cancers
EP1891111A1 (en) 2005-05-06 2008-02-27 ZymoGenetics, Inc. Il-31 monoclonal antibodies and methods of use
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en) 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
WO2007133816A2 (en) * 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP2006381B1 (en) 2006-03-31 2016-02-03 Chugai Seiyaku Kabushiki Kaisha Method for controlling blood pharmacokinetics of antibodies
JP5043008B2 (ja) * 2006-06-08 2012-10-10 中外製薬株式会社 炎症性疾患の予防または治療剤
EP2061811A2 (en) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US20100003704A1 (en) 2008-06-13 2010-01-07 Shuling Cheng IN SITU detection of early stages and late stages HPV infection
JP2010515755A (ja) 2007-01-10 2010-05-13 ザイモジェネティクス， インコーポレイテッド 気道過敏および喘息を処置するためのｉｌ−３１の使用法
US9688762B2 (en) 2007-09-26 2017-06-27 Chugai Sciyaku Kabushiki Kaisha Modified antibody constant region
EP4368721A2 (en) 2007-09-26 2024-05-15 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
WO2009052487A2 (en) * 2007-10-18 2009-04-23 University Of South Florida Method of detecting oncogenesis of hematopoietic cells
TWI441649B (zh) * 2007-12-05 2014-06-21 Chugai Pharmaceutical Co Ltd Use of anti-NR10 monoclonal antibody with neutralizing activity against NR10 in the manufacture of prophylactic or therapeutic agents for pruritus
CN101939424B (zh) * 2007-12-05 2016-12-28 中外制药株式会社 抗nr10抗体及其应用
EP2471817B1 (en) 2007-12-07 2016-03-16 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31
NO2708559T3 (no) 2008-04-11 2018-08-25
EP2285982B1 (en) 2008-05-27 2018-04-11 Dako Denmark A/S Compositions and methods for detection of chromosomal aberrations with novel hybridization buffers
WO2010097655A1 (en) 2009-02-26 2010-09-02 Dako Denmark A/S Compositions and methods for rna hybridization applications
JP2010210772A (ja) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd 液晶表示装置の製造方法
TWI646193B (zh) 2009-03-19 2019-01-01 中外製藥股份有限公司 抗體恆定區域改變體
EP2409991B1 (en) 2009-03-19 2017-05-03 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US8892184B2 (en) 2010-10-18 2014-11-18 Siemens Medical Solutions Usa, Inc. Systems and methods for reducing interference in a dual modality imaging system
AU2011337704B2 (en) 2010-11-30 2017-06-15 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US8790651B2 (en) * 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
WO2013025248A1 (en) * 2011-08-12 2013-02-21 Mello Biotechnology, Inc. Inducable expression from the eukaryotic pol -2 promoter in prokaryotes
US10662465B2 (en) 2011-09-30 2020-05-26 Agilent Technologies, Inc. Hybridization compositions and methods using formamide
EP2768974B1 (en) 2011-10-21 2017-07-19 Dako Denmark A/S Hybridization compositions and methods
US10196662B2 (en) * 2012-08-10 2019-02-05 Mello Biotechnology, Inc. Composition for producing microRNA precursors as drugs for enhancing wound healing and production method of the microRNA precursors
EP3004167B1 (en) 2013-05-30 2018-07-25 Kiniksa Pharmaceuticals, Ltd. Oncostatin m receptor antigen binding proteins
US10464982B2 (en) 2014-04-23 2019-11-05 Emory University Compositions of GM-CSF and interleukin fusions for immune modulation and uses related thereto
US20170072019A1 (en) * 2014-05-12 2017-03-16 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising il-31 and uses thereof
CA2980992C (en) 2015-04-14 2024-01-23 Akihisa Kaneko Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
CN104826100A (zh) * 2015-04-16 2015-08-12 浙江海隆生物科技有限公司 一种猪瘟病毒重组亚单位疫苗的制备方法与应用
DE102015215840B4 (de) * 2015-08-19 2017-03-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Multiaperturabbildungsvorrichtung, Abbildungssystem und Verfahren zum Bereitstellen einer Multiaperturabbildungsvorrichtung
US10093731B2 (en) 2017-02-24 2018-10-09 Kindred Biosciences, Inc. Anti-IL31 antibodies for veterinary use
AR120512A1 (es) 2019-11-20 2022-02-16 Chugai Pharmaceutical Co Ltd Formulaciones que contienen anticuerpos
CN111337666B (zh) * 2020-02-12 2021-04-02 山东大学 I-motif重组介导的FRET探针及其原位成像癌细胞表面蛋白质同源二聚化的应用
TWI765431B (zh) * 2020-11-25 2022-05-21 長庚大學 核酸放大系統及其方法

Family Cites Families (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4054646A (en) * 1973-07-30 1977-10-18 General Electric Method and apparatus for detection of antibodies and antigens
US4615974A (en) 1981-08-25 1986-10-07 Celltech Limited Yeast expression vectors
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4486533A (en) 1982-09-02 1984-12-04 St. Louis University Filamentous fungi functional replicating extrachromosomal element
US4599311A (en) 1982-08-13 1986-07-08 Kawasaki Glenn H Glycolytic promotersfor regulated protein expression: protease inhibitor
US4977092A (en) 1985-06-26 1990-12-11 Amgen Expression of exogenous polypeptides and polypeptide products including hepatitis B surface antigen in yeast cells
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4603044A (en) 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
US4661454A (en) 1983-02-28 1987-04-28 Collaborative Research, Inc. GAL1 yeast promoter linked to non galactokinase gene
US5139936A (en) 1983-02-28 1992-08-18 Collaborative Research, Inc. Use of the GAL1 yeast promoter
US4650764A (en) 1983-04-12 1987-03-17 Wisconsin Alumni Research Foundation Helper cell
US4870008A (en) 1983-08-12 1989-09-26 Chiron Corporation Secretory expression in eukaryotes
US4931373A (en) 1984-05-25 1990-06-05 Zymogenetics, Inc. Stable DNA constructs for expression of α-1 antitrypsin
US4766073A (en) 1985-02-25 1988-08-23 Zymogenetics Inc. Expression of biologically active PDGF analogs in eucaryotic cells
ATE54167T1 (de) 1984-12-06 1990-07-15 Fina Research Promotoren fuer die expression von fremden genen in hefe, plasmide, die diese promotoren enthalten, sowie deren verwendung zur herstellung von polypeptiden.
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
US4882279A (en) 1985-10-25 1989-11-21 Phillips Petroleum Company Site selective genomic modification of yeast of the genus pichia
US4935349A (en) 1986-01-17 1990-06-19 Zymogenetics, Inc. Expression of higher eucaryotic genes in aspergillus
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4980289A (en) 1987-04-27 1990-12-25 Wisconsin Alumni Research Foundation Promoter deficient retroviral vector
US5063154A (en) 1987-06-24 1991-11-05 Whitehead Institute For Biomedical Research Pheromone - inducible yeast promoter
US5567584A (en) 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
DE721983T1 (de) 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
US4956288A (en) 1988-04-22 1990-09-11 Biogen, Inc. Method for producing cells containing stably integrated foreign DNA at a high copy number, the cells produced by this method, and the use of these cells to produce the polypeptides coded for by the foreign DNA
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5162228A (en) 1988-12-28 1992-11-10 Takeda Chemical Industries, Ltd. Gylceraldehyde-3-phosphate dehydrogenase gene and promoter
US5124263A (en) 1989-01-12 1992-06-23 Wisconsin Alumni Research Foundation Recombination resistant retroviral helper cell and products produced thereby
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
US5162222A (en) 1989-07-07 1992-11-10 Guarino Linda A Use of baculovirus early promoters for expression of foreign genes in stably transformed insect cells or recombinant baculoviruses
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
JP3202999B2 (ja) 1991-01-31 2001-08-27 協和醗酵工業株式会社 肝移行性リポソーム製剤
US5298418A (en) 1991-09-16 1994-03-29 Boyce Thompson Institute For Plant Research, Inc. Cell line isolated from larval midgut tissue of Trichoplusia ni
US5641670A (en) 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
EP0749319A1 (en) 1992-09-14 1996-12-27 Pfizer Inc. Immortalized cells and uses therefor
AU7477394A (en) 1993-07-30 1995-03-27 University Of Medicine And Dentistry Of New Jersey Efficient gene transfer into primary lymphocytes
US6117679A (en) 1994-02-17 2000-09-12 Maxygen, Inc. Methods for generating polynucleotides having desired characteristics by iterative selection and recombination
US5492841A (en) * 1994-02-18 1996-02-20 E. I. Du Pont De Nemours And Company Quaternary ammonium immunogenic conjugates and immunoassay reagents
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
RU2102988C1 (ru) * 1995-02-10 1998-01-27 Зинченко Елена Вениаминовна Препарат с иммуномодулирующими свойствами
US6074849A (en) 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
JP2000500014A (ja) 1995-11-09 2000-01-11 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカ中で異種ポリペプチドを生産するための組成物と方法
US6265184B1 (en) * 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US5792850A (en) 1996-05-23 1998-08-11 Zymogenetics, Inc. Hematopoietic cytokine receptor
JP2002514049A (ja) 1996-07-17 2002-05-14 ザイモジェネティクス，インコーポレイティド ピヒア・メタノリカの栄養要求性突然変異体の製造
CA2261151C (en) 1996-07-17 2003-09-16 Zymogenetics, Inc. Transformation of pichia methanolica
PT1500329E (pt) 1996-12-03 2012-06-18 Amgen Fremont Inc Anticorpos humanos que se ligam especificamente ao tnf alfa humano
GB9819420D0 (en) 1998-09-07 1998-10-28 Glaxo Group Ltd Novel receptor
AU4711800A (en) * 1999-05-11 2000-11-21 Zymogenetics Inc. Cytokine receptor mouse zcytor10
PT1188830E (pt) 1999-06-02 2010-04-09 Chugai Pharmaceutical Co Ltd Nova proteína nr10 receptora da hemopoietina
AU6531101A (en) 2000-06-02 2001-12-17 Genentech Inc Secreted and transmembrane polypeptides and nucleic acids encoding the same
CA2412211A1 (en) 2000-06-23 2002-01-03 Genetech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2258725A3 (en) 2000-06-26 2014-09-17 ZymoGenetics, L.L.C. Cytokine receptor zcytor17
US20030096339A1 (en) 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
AU2001273150A1 (en) 2000-07-20 2002-02-05 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
MXPA03002971A (es) 2000-10-06 2004-05-05 Immunex Corp Receptores de hematopoyetina hpr1 y hpr2.
WO2002077230A1 (fr) 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Variants d'epissage nr10
RU2360923C2 (ru) 2002-01-18 2009-07-10 Займоджинетикс, Инк. Новый лиганд рецептора цитокина zcytor17
US7494804B2 (en) 2002-01-18 2009-02-24 Zymogenetics, Inc. Polynucleotide encoding cytokine receptor zcytor17 multimer
ATE431406T1 (de) 2002-02-25 2009-05-15 Genentech Inc Neuer typ-1-cytokinrezeptor glm-r
CA2593488A1 (en) * 2005-01-19 2006-07-27 Irm Llc Multi-well container positioning devices, systems, computer program products, and methods
US20060228329A1 (en) 2005-01-28 2006-10-12 Brady Lowell J Homogeneous preparations of IL-31
EP1856150A2 (en) 2005-02-14 2007-11-21 ZymoGenetics, Inc. Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
MX2007009718A (es) 2005-02-14 2007-09-26 Zymogenetics Inc Metodos para tratar trastornos cutaneos utilizando un antagonista il-31ra.
EP1891111A1 (en) * 2005-05-06 2008-02-27 ZymoGenetics, Inc. Il-31 monoclonal antibodies and methods of use
US20130216542A1 (en) 2005-05-06 2013-08-22 Zymogenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
US8101183B2 (en) * 2005-05-06 2012-01-24 Zymogentics, Inc. Variable region sequences of IL-31 monoclonal antibodies
WO2007133816A2 (en) 2006-01-10 2007-11-22 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31ra and osmrb antagonists
EP2061811A2 (en) 2006-09-01 2009-05-27 ZymoGenetics, Inc. Variable region sequences of il-31 monoclonal antibodies and methods of use
JP2010515755A (ja) 2007-01-10 2010-05-13 ザイモジェネティクス， インコーポレイテッド 気道過敏および喘息を処置するためのｉｌ−３１の使用法
EP2471817B1 (en) 2007-12-07 2016-03-16 ZymoGenetics, Inc. Humanized antibody molecules specific for IL-31

Also Published As

Publication number Publication date
IL210455A0 (en) 2011-03-31
EP1476541A2 (en) 2004-11-17
RU2008118227A (ru) 2009-11-20
EP1476541A4 (en) 2006-01-11
US7531636B2 (en) 2009-05-12
WO2003060090A2 (en) 2003-07-24
US8778344B2 (en) 2014-07-15
BR0306979A (pt) 2004-11-23
US8013124B2 (en) 2011-09-06
PL371586A1 (en) 2005-06-27
ES2377188T3 (es) 2012-03-23
EP2230299B1 (en) 2011-12-07
ATE401390T1 (de) 2008-08-15
US20090149635A1 (en) 2009-06-11
US20070249020A1 (en) 2007-10-25
US7740834B2 (en) 2010-06-22
JP2005526494A (ja) 2005-09-08
US8124378B2 (en) 2012-02-28
DK1961811T3 (da) 2010-11-08
DE60333963D1 (de) 2010-10-07
DK2230299T3 (da) 2012-03-26
US20180155418A1 (en) 2018-06-07
ZA200405695B (en) 2005-03-30
EP1476541B1 (en) 2008-07-16
EP2230299A1 (en) 2010-09-22
US9605062B2 (en) 2017-03-28
US7459293B2 (en) 2008-12-02
ATE478944T1 (de) 2010-09-15
US7064186B2 (en) 2006-06-20
ES2351678T3 (es) 2011-02-09
US20130156695A1 (en) 2013-06-20
EP1961811A1 (en) 2008-08-27
KR20040082394A (ko) 2004-09-24
IL163066A (en) 2011-08-31
IL210454A (en) 2014-02-27
AU2003225525A1 (en) 2003-07-30
US20110196128A1 (en) 2011-08-11
CA2473686A1 (en) 2003-07-24
CN101843895A (zh) 2010-09-29
US20070077627A1 (en) 2007-04-05
US20190338020A1 (en) 2019-11-07
US20030224487A1 (en) 2003-12-04
NO20043419L (no) 2004-10-18
SI2230299T1 (sl) 2012-07-31
KR101013401B1 (ko) 2011-02-14
IL210455A (en) 2014-02-27
US20060141579A1 (en) 2006-06-29
US7425325B2 (en) 2008-09-16
WO2003060090A3 (en) 2004-04-01
RU2490276C2 (ru) 2013-08-20
AU2008230054A1 (en) 2008-11-13
DE60322188D1 (de) 2008-08-28
CN100575482C (zh) 2009-12-30
US20150010946A1 (en) 2015-01-08
CY1112833T1 (el) 2016-02-10
AU2003225525B2 (en) 2008-07-24
PL211833B1 (pl) 2012-06-29
EP1961811B1 (en) 2010-08-25
US7507795B2 (en) 2009-03-24
CN1643138A (zh) 2005-07-20
RU2004125165A (ru) 2005-04-20
NO332266B1 (no) 2012-08-13
RU2360923C2 (ru) 2009-07-10
PT2230299E (pt) 2012-03-02
US20090192292A1 (en) 2009-07-30
AU2008230054B2 (en) 2012-01-19
ATE536406T1 (de) 2011-12-15
US20070111266A1 (en) 2007-05-17
IL210454A0 (en) 2011-03-31
CA2473686C (en) 2011-09-20
ES2310660T3 (es) 2009-01-16
JP4795641B2 (ja) 2011-10-19

Similar Documents

Publication Publication Date Title
DK1476541T3 (da) Cytokin (zcytor17-ligand)
DK1576112T3 (da) Cytokin-receptor zcytor17-multimerer
ATE497975T1 (de) Il-21-varianten
ATE392430T1 (de) Verfahren zur herstellung von dipeptiden
ATE450619T1 (de) Defructosylierungsverfahren
ATE417275T1 (de) Puffern zur stabilizierung von hcv antigenen
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
ATE390441T1 (de) Niedrigallergene proteinvarianten
DE60329070D1 (de) Antikörper gegen den fibroblastenwachstumsfaktor 23
ATE446104T1 (de) Rekombinantes super-verbindungs-interferon zur verwendung als hepatitis b oberflächenatigen und e-antigen-inhibitor
ATE495247T1 (de) Chromoprotein und fluoroproteine
DK1114156T3 (da) Transformerende vækstfaktor Beta-9 (ZTGFSS9) fra pattedyr
ATE403726T1 (de) Cytokin-proteinfamilie
WO2002102847A1 (fr) Nouveau ligand et son adn
CA2441187A1 (en) Acetyllysine-recognizing monoclonal antibody and process for producing the same
DK0994187T3 (da) Renin-aktivt stof omfattende humant prorenin og antistoffer mod prorenin-profragmentet
LV12722A (lv) Prv-1 gene and the use thereof